Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | IDO1 | P14902 | 4/20 | 0.44 |
| ▸ | CBX7 | O95931 | 6/20 | 0.43 |
| ▸ | CDYL | Q9Y232 | 6/20 | 0.43 |
| ▸ | CDYL2 | Q8N8U2 | 5/20 | 0.43 |
| ▸ | CDY1; CDY1B | Q9Y6F8 | 4/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | KMO | O15229 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4413144 | 0.82 | HPGD (0.64) | HPGDIDO1CBX7CDYLCDYL2 | |
| SCHEMBL655852 | 0.77 | HPGD (0.66) | HPGDIDO1CBX7CDYLCDYL2 | |
| SCHEMBL4414360 | 0.76 | HPGD (0.64) | HPGDIDO1KMO | |
| SCHEMBL29958110 | 0.76 | IDO1 (0.71) | HPGDIDO1KMO | |
| SCHEMBL4411794 | 0.76 | HPGD (0.64) | HPGDCBX7CDYLCDYL2CDY1; CDY1B | |
| SCHEMBL16250472 | 0.76 | HPGD (0.64) | HPGDSMN1; SMN2 | |
| SCHEMBL16601597 | 0.76 | HPGD (0.64) | HPGDMAPK1SMN1; SMN2 | |
| SCHEMBL4414345 | 0.74 | HPGD (1.00) | HPGDIDO1CBX7CDYLCDYL2 | |
| SCHEMBL4417498 | 0.73 | HPGD (0.60) | HPGDIDO1MAPK1SMN1; SMN2 | |
| SCHEMBL4418860 | 0.73 | HPGD (0.52) | HPGDIDO1MAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1756071-B1 | BENZOXAZOLONE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB PHARMA SA (BE) | 2009-08-26 | — | — | EP | claimed |
| US-20070299118-A1 | Benzoxazolone Derivatives, Processes For Preparing Them And Their Uses | UCB, S.A. (BE) | 2007-12-27 | — | — | US | claimed |
| EP-1756071-A1 | BENZOXAZOLONE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB, S.A. (BE) | 2007-02-28 | — | — | EP | claimed |
| WO-2005118561-A1 | BENZOXAZOLONE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB, S.A. (BE) | 2005-12-15 | — | — | WO | claimed |
| US-8293775-B2 | Benzoxazolone derivatives, processes for preparing them and their uses | UCB PHARMA, S.A. (BE) | 2012-10-23 | — | — | US | disclosed |
| EP-1756071-B1 | BENZOXAZOLONE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB PHARMA SA (BE) | 2009-08-26 | — | — | EP | disclosed |
| US-20070299118-A1 | Benzoxazolone Derivatives, Processes For Preparing Them And Their Uses | UCB, S.A. (BE) | 2007-12-27 | — | — | US | disclosed |
| EP-1756071-A1 | BENZOXAZOLONE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB, S.A. (BE) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005118561-A1 | BENZOXAZOLONE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB, S.A. (BE) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299118-A1 | Benzoxazolone Derivatives, Processes For Preparing Them And Their Uses | PARK7, SNCA, GABRA5 | HPGD 232/4885IDO1 1662/4885CBX7 334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.